
Paras Healthcare Ltd.
PARASHLTH
Equity
BSE,NSE
Min. Investment :
₹6,60,000.00
IPO Details
Bidding Dates
21 Oct 26-23 Oct 26
Price Range ₹
660 -693
Total Equity
₹ 837.37Cr
Lot Size
21
Exchange Status
BSE,NSE
Subscription Rate
Non-Institutional Investor
2.00×
Qualified Institutional Buyers
3.09×
Employees
0.00×
Retail Investors
2.00×
Total subscription Rate
2.23×
IPO Timeline
Offer start
21 Oct 2026
Offer end
23 Oct 2026
Allotment
26 Oct 2026
Refund initiation
27 Oct 2026
Demat transfer
27 Oct 2026
Listing
--
About Company
Paras Health is the fifth-largest healthcare provider in North India, Bihar, and Jharkhand based on bed capacity, operating 2,135 beds across eight hospitals as of March 31, 2024. The company specializes in tertiary care services, focusing on Tier 2 and Tier 3 cities with key clinical areas such as cardiac sciences, oncology, and orthopedics. With 18 years of experience, Paras Health follows an asset-light expansion strategy to grow in underserved regions. It aims to increase its bed capacity to 2,935 by 2029 with new hospitals planned in Gurugram and Ludhiana. Additionally, the company is investing in digital healthcare solutions to enhance patient care.
Year Founded
21-12-1987
Promotor Details
Saurabh Sood
Offer to Public
1,20,83,331.00 Cr
Promoter Holdings Details
| Particular | Pre-IPO | Post-IPO |
|---|---|---|
Percentage | 75.32 | 0 |
Share Capital | 73519240 | 0 |
Project Details
Prepayment or scheduled re-payment of a portion of certain outstanding borrowings availed by our Com -3209cr
Investment in our wholly owned Subsidiary, PMHPL (which also operates our hospital in Srinagar) -541cr
Objectives
Prepayment or scheduled re-payment, in full or part, of certain outstanding borrowings availed by our CompanyInvestment in our wholly owned Subsidiary, PMHPL (which also operates our hospital in Srinagar), for repayment/prepayment of borrowings, in full or part, of PMHPLGeneral corporate purposes
Highlights
Positioned as a leading healthcare provider in underserved markets of North India with a first-mover advantage.
Asset-light approach enhances operational efficiency and drives patient accessibility.
Strong ability to attract and retain top medical talent, ensuring high-quality patient care.
Presence across multiple specialties, payor mixes, and geographic locations reduces reliance on any single segment.
Robust infrastructure, advanced technology, and a experienced, doctor-led management team provide a solid foundation for growth.
Challenges
A history of losses raises concerns about the company's financial stability and future profitability.
Dependence on attracting and retaining skilled healthcare professionals creates vulnerability to staffing challenges.
Regulatory changes and pharmaceutical pricing uncertainties could negatively impact financial performance.
Reliance on in-patient revenue and occupancy rates exposes the company to fluctuations in demand and pricing.
Non-exclusive doctor arrangements and potential non-compliance with regulations pose operational and financial risks.
Financials
| Years | Total Assets | Share Capital | Profit After Tax | Consolidated Net Profit | Adjusted EPS |
|---|---|---|---|---|---|
2022 | 9,635.28 | 36.76 | -579.83 | -579.83 | -5.9403 |
2026 | 20,711.41 | 100.99 | -148.08 | -148.08 | -2.0141 |
2023 | 12,931.01 | 36.76 | -579.83 | -579.83 | -5.9403 |
2024 | 14,776.58 | 97.61 | 386.50 | 386.50 | 5.2571 |
2025 | 18,104.51 | 97.61 | -253.52 | -258.85 | -3.5208 |